NCT00828958View on ClinicalTrials.gov

Injection Site Tolerability of Multiple Dose Treatment With Long-acting Injectable Risperidone Administered Via Deltoid Muscle in Chronic Schizophrenia Patients.

PHASE3CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

February 28, 2006

Study Completion Date

September 30, 2006

Conditions
Schizophrenia
Interventions
DRUG

Risperidone long-acting injectable

All Listed Sponsors
lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00828958 - Injection Site Tolerability of Multiple Dose Treatment With Long-acting Injectable Risperidone Administered Via Deltoid Muscle in Chronic Schizophrenia Patients. | Biotech Hunter | Biotech Hunter